Lantern Pharma Inc. (Nasdaq: LTRN)
Edit

Lantern Pharma Inc. (Nasdaq: LTRN)

http://www.lanternpharma.com/
Last activity: 30.05.2026
Active
Categories: Artificial IntelligenceBioTechDataDevelopmentDrugHealthTechLearnMedtechPersonalPlatform
Lantern Pharma, Inc. is a clinical stage pharmaceutical company developing new classes of precision cancer drugs with novel mechanisms of action, and also rescuing or revitalizing abandoned or failed cancer drugs using machine learning techniques, genomic data and precision oncology trials.

Lantern Pharma recognizes that the high cost and low success rates in oncology drug development largely stem from the inability to appropriately stratify patient populations prior to enrollment, and also from the inability to fully elucidate mechanisms of action that can suggest potent combinations. Our approach which leverages our RADR platform helps to provide rapid, meaningful insight to both of these central problems in oncology.

Lantern is focused on accelerating personalized cancer therapy development through the use of AI and genomic-based patient stratification.
Followers
433
Followers
1.27K
Mentions
52
Location: United States, Texas, Dallas
Employees: 11-50
Total raised: $72.7M
Founded date: 2013
Twitter
LinkedIn
Youtube
Email

Investors 1

Funding Rounds 2

DateSeriesAmountInvestors
14.01.2021-$69M-
02.05.2017Series A$3.7M-

Mentions in press and media 52

DateTitleDescription
30.05.2026New to The Street Broadcasts Nationwide on Bloomberg Television Featuring "Opportunities To Consider(TM)" Across Artificial Intelligence, Healthcare Innovation, Fintech, Digital Assets, and ...NEW YORK CITY, NY / ACCESS Newswire / May 30, 2026 / New to The Street announces tonight's Bloomberg Television broadcast airing at 6:30 PM ET as sponsored programming across the United States, MENA, and Latin America. This week's program f...
23.05.2026New to The Street Broadcasts Episode 753 Today at 6:30 PM EST Across Bloomberg Television U.S., MENA, and Latin America Featuring Leaders in VR Defense Training, AI Streaming, Healthcare Innovation, a...Featured companies include Virtuix Holdings (NASDAQ:VTIX), Medicus Pharma (NASDAQ:MDCX), YY Group Holding Limited (NASDAQ:YYGH), and FreeCast (NASDAQ:AST). The show also broadcasts as sponsored programming with featured commercial segments ...
01.09.2023Daily AI Roundup: Biggest Machine Learning, Robotic And Automation Updates 1st Sept 2023This is our AI Daily Roundup . We are covering the top updates from around the world. The updates will feature state-of-the-art capabilities in artificial intelligence (AI), Machine Learning, Robotic Process Automation, Fintech, and human-s...
31.08.2023Lantern Pharma Expands AI Capabilities of RADR Platform to Accelerate the Clinical Development of Immune Checkpoint InhibitorsExpansion of RADR platform adds new AI capabilities for the automated identification of new and effective combination therapy regimens for immune checkpoint inhibitors (ICI) Additional functionality includes the creation and testing of mole...
12.06.2023Lantern Pharma Receives FDA Clearance of IND Application for Drug Candidate LP-184 in Solid TumorsLantern Pharma, an artificial intelligence (“AI”) company developing targeted and transformative cancer therapies using its proprietary RADR AI and machine learning (“ML”) platform with multiple clinical stage drug programs, announced that ...
09.06.2023Lantern Pharma Leverages AI Platform, RADR, to Develop Breakthrough Antibody Drug Conjugates (ADCs) in Collaboration with Bielefeld UniversityLantern will leverage its proprietary AI platform, RADR, to rapidly develop novel cryptophycin-antibody drug conjugates (ADCs), which represent an exciting class of potent and highly targeted drug candidates. The collaboration with Bielefel...
06.03.2023Lantern Pharma Announces Formation of Starlight Therapeutics to Advance Transformative Therapies for CNS (Central Nervous System) and Brain CancersLantern Pharma, a clinical-stage biopharmaceutical company using its proprietary RADR artificial intelligence (AI) and machine learning (ML) platform to transform the cost, pace, and timeline of oncology drug discovery and development, toda...
15.02.2023Lantern Pharma Further Enhances Capabilities of its AI Drug Discovery Platform, RADR, with Product Development Roadmap for the Development of Antibody Drug ConjugatesLantern Pharma, a clinical stage biopharmaceutical company using its proprietary RADR artificial intelligence (“AI”) and machine learning (“ML”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, ...
11.10.2022Lantern Pharma to Present at The MicroCap Rodeo Presents The Windy City Roundup 2022 on Wednesday, October 12 at 11:00 a.m. ETDALLAS, TX / ACCESSWIRE / October 11, 2022 / Lantern Pharma Inc. (NASDAQ:LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") and machine learning ("M.L.") platfo...
24.01.2022Lantern Pharma Receives Rare Pediatric Disease and Orpan Drug Designations for LP-184 for the Treatment of Atypical Teratoid Rhabdoid Tumor (ATRT) - an Aggressive and Rapidly Growing Form of Cancer of...DALLAS, Jan. 24, 2022 /PRNewswire/ -- Lantern Pharma (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence ("A.I.") platform to transform the cost, pace, and timeline of onc...
Show more

Reviews 0

Sign up to leave a review

Sign up Log In